Results 31 to 40 of about 144,436 (251)

Bell's palsy during rechallenge of immune checkpoint inhibitor

IJU Case Reports, 2023
Introduction The peripheral nervous system is one of the target organs of immune‐related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features ...
Kohji Takemura, Taro Yamanaka, Michikata Hayashida, Rika Kizawa, Takeshi Yamaguchi, Yuko Tanabe, Kazushige Sakaguchi, Koichi Suyama, Shinji Urakami, Yuji Miura   +9 more
doaj   +1 more source

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?

Frontiers in Immunology, 2022
Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian, Xinye Qian, Wang Hu, Wang Hu, Jun Yan, Jun Yan   +5 more
doaj   +1 more source

Immune Checkpoint Inhibitor Therapy Associated Hypophysitis

Clinical Medicine Insights: Endocrinology and Diabetes, 2015
Ipilimumab is a monoclonal antibody directed against CTLA4 T-lymphocyte antigen used as cancer therapy. Immune-related adverse events are common side effects and may include hypophysitis-related hypopituitarism. The clinical features of six patients with
Moeber Mahzari, Dora Liu, Amel Arnaout, Heather Lochnan   +3 more
doaj   +2 more sources

Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report

Journal of Medical Case Reports, 2018
Background Novel immune checkpoint inhibitors have been often utilized for different types of malignancies as salvage therapy with varying success. One obstacle to immune checkpoint inhibitor use is the higher incidence of immune-mediated side effects ...
Linh Ngo, Eric Miller, Peter Valen, Elie Gertner   +3 more
doaj   +1 more source

Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung

Case Reports in Dermatological Medicine, 2022
Immune checkpoint inhibitors are associated with a spectrum of cutaneous immune-related adverse events. While maculopapular eruptions are the most common cutaneous adverse event, scleroderma can rarely develop.
Jeffrey L. Dobrzynski, Blake E. Vest, Brian L. Swick   +2 more
doaj   +1 more source

Efficacy and Safety of Immune Checkpoint Inhibitors Therapy on Advanced Gastric Cancer or Gastroesophageal Junction Cancer: A Meta-analysis

Zhongliu Fangzhi Yanjiu, 2021
Objective To systematically evaluate the efficacy and safety of immune checkpoint inhibitors in the treatment of advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC).
SHAN Yujie, LIANG Ping, LYU Yalei, WANG Long, ZHANG Xiaolin, SHAN Baoen   +5 more
doaj   +1 more source

Cardiotoxicity of immune checkpoint inhibitors

ESMO Open, 2017
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity. Immune checkpoint inhibitors are a novel class of anticancer drugs, distinct from targeted or tumour type-specific therapies.
VARRICCHI, GILDA, GALDIERO, MARIA ROSARIA, MARONE, GIANCARLO, CRISCUOLO, GJADA, TRIASSI, MARIA, BONADUCE, DOMENICO, MARONE, GIANNI, TOCCHETTI, CARLO GABRIELE   +7 more
openaire   +3 more sources

Negative Immune Checkpoint Inhibitors

Pharmaceutics
Checkpoint inhibitors are a modern therapeutic approach for treating various types of cancer, metabolic diseases, and chronic infections. The main goal of this therapy is to specifically unlock the immune system, allowing it to recognize and eliminate cancer cells or pathogens, primarily through the activation of T lymphocytes.
Magda Drewniak-Świtalska, Paulina Fortuna, Małgorzata Krzystek-Korpacka   +2 more
openaire   +4 more sources

Unsuccessful rechallenge with nivolumab in a patient with advanced non‐small cell lung cancer who had a 6‐year complete response and treatment‐free period: Case report

Respirology Case Reports
Several predictive factors of immune checkpoint inhibitor response have been reported, but there has not been sufficient exploration of which patients benefit from immune checkpoint inhibitor rechallenge.
Toshiaki Takakura, Hiroaki Akamatsu, Atsushi Washioka, Eriko Murakami, Ryota Shibaki, Toshio Shimizu, Yasuhiro Koh, Nobuyuki Yamamoto   +7 more
doaj   +1 more source

Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature

Respiratory Medicine Case Reports, 2019
Immune checkpoint inhibitors are known to cause a variety of immune-related adverse events, including pneumonitis. When symptomatic, treatment typically consists of temporary or permanent cessation of the checkpoint inhibitor and several weeks of ...
Camille R. Petri, Rushad Patell, Felipe Batalini, Deepa Rangachari, Robert W. Hallowell   +4 more
doaj   +1 more source